The estimated Net Worth of Tanya Lewis is at least $2.06 Million dollars as of 13 June 2023. Ms Lewis owns over 12,860 units of Replimune Inc stock worth over $1,402,988 and over the last 5 years she sold REPL stock worth over $641,353. In addition, she makes $16,235 as Chief Devel. Operations Officer at Replimune Inc.
Ms has made over 6 trades of the Replimune Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 12,860 units of REPL stock worth $309,412 on 13 June 2023.
The largest trade she's ever made was selling 12,860 units of Replimune Inc stock on 13 June 2023 worth over $309,412. On average, Ms trades about 2,438 units every 60 days since 2020. As of 13 June 2023 she still owns at least 135,293 units of Replimune Inc stock.
You can see the complete history of Ms Lewis stock trades at the bottom of the page.
Tanya N. Lewis M.S. is the Chief Devel. Operations Officer at Replimune Inc.
As the Chief Devel. Operations Officer of Replimune Inc, the total compensation of Ms S at Replimune Inc is $16,235. There are 7 executives at Replimune Inc getting paid more, with Pradeep Misra having the highest compensation of $7,920,000.
Ms S is 50, she's been the Chief Devel. Operations Officer of Replimune Inc since . There are 4 older and 2 younger executives at Replimune Inc. The oldest executive at Replimune Group Inc is Dr. Colin A. Love Ph.D., 63, who is the Chief Operating Officer.
Tanya's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.
Over the last 6 years, insiders at Replimune Inc have traded over $72,652,546 worth of Replimune Inc stock and bought 2,360,000 units worth $33,565,200 . The most active insiders traders include Group, Llc Green Jeremy Red..., Capital Life Sciences Inves... und Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of $508,649. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth $90,989.
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Replimune Inc executives and other stock owners filed with the SEC include: